Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Prolonged-release famprid… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Prolonged-release fampridine and walking and balance in MS: Randomised controlled MOBILE trial

Artikel i vetenskaplig tidskrift
Författare Raymond Hupperts
Jan Lycke
Christine Short
Claudio Gasperini
Manjit McNeill
Rossella Medori
Agata Tofil-Kaluza
Maria Hovenden
Lahar R. Mehta
Jacob Elkins
Publicerad i Multiple Sclerosis
Volym 22
Sidor 212-221
ISSN 1352-4585
Publiceringsår 2016
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 212-221
Språk en
Länkar dx.doi.org/10.1177/1352458515581436
Ämnesord balance, Fampridine, multiple sclerosis, randomised clinical trial, walking
Ämneskategorier Neurovetenskaper

Sammanfattning

© SAGE Publications.Background: Mobility impairment is a common disability in MS and negatively impacts patients' lives. Objective: Evaluate the effect of prolonged-release (PR) fampridine (extended-release dalfampridine in the United States) on self-assessed walking disability, dynamic/static balance and safety in patients with MS. Methods: MOBILE was a randomised, double-blind, exploratory, placebo-controlled trial. Patients with progressive/relapsing-remitting MS and Expanded Disability Status Scale score of 4.0-7.0 were treated with PR-fampridine or placebo twice daily for 24 weeks. Efficacy endpoints included change from baseline in the 12-item MS Walking Scale (MSWS-12), Timed Up and Go (TUG) test and Berg Balance Scale (BBS). Results: 132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks. A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds ≥7 (p = 0.0275), ≥8 (p = 0.0153) and ≥9 points (p = 0.0088) and TUG speed thresholds ≥10% (p = 0.0021) and ≥15% (p = 0.0262). PR-fampridine was well tolerated. Conclusions: PR-fampridine therapy resulted in early and sustained improvements in broad measures of walking and balance over six months.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?